CN115337348A - Traditional Chinese medicine composition for treating heat accumulation and blood vessels - Google Patents
Traditional Chinese medicine composition for treating heat accumulation and blood vessels Download PDFInfo
- Publication number
- CN115337348A CN115337348A CN202210933899.7A CN202210933899A CN115337348A CN 115337348 A CN115337348 A CN 115337348A CN 202210933899 A CN202210933899 A CN 202210933899A CN 115337348 A CN115337348 A CN 115337348A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- chinese medicine
- traditional chinese
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 126
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 210000004204 blood vessel Anatomy 0.000 title claims abstract description 23
- 238000009825 accumulation Methods 0.000 title claims abstract description 15
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 60
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 58
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 58
- 239000002994 raw material Substances 0.000 claims abstract description 55
- 235000002226 Ranunculus ficaria Nutrition 0.000 claims abstract description 53
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 52
- 229940079593 drug Drugs 0.000 claims abstract description 49
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 48
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 48
- 244000153955 Reynoutria sachalinensis Species 0.000 claims abstract description 40
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 claims abstract description 40
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 35
- 235000011477 liquorice Nutrition 0.000 claims abstract description 35
- 241000304195 Salvia miltiorrhiza Species 0.000 claims abstract 10
- 241000213006 Angelica dahurica Species 0.000 claims abstract 7
- 239000000284 extract Substances 0.000 claims description 165
- 241001530126 Scrophularia Species 0.000 claims description 53
- 239000008187 granular material Substances 0.000 claims description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 241000555712 Forsythia Species 0.000 claims description 28
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 24
- 240000001341 Reynoutria japonica Species 0.000 claims description 19
- 235000018167 Reynoutria japonica Nutrition 0.000 claims description 19
- 241000576429 Forsythia suspensa Species 0.000 claims description 16
- 238000000605 extraction Methods 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 16
- 229940069445 licorice extract Drugs 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 10
- 239000006187 pill Substances 0.000 claims description 5
- 239000006186 oral dosage form Substances 0.000 claims description 4
- 239000009724 Salvia extract Substances 0.000 claims description 3
- 239000000469 ethanolic extract Substances 0.000 claims description 3
- 238000007670 refining Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 241000125175 Angelica Species 0.000 claims 4
- 241000555682 Forsythia x intermedia Species 0.000 abstract 1
- 244000081426 Ranunculus ficaria Species 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 49
- 244000132619 red sage Species 0.000 description 42
- 241000382455 Angelica sinensis Species 0.000 description 29
- 208000011580 syndromic disease Diseases 0.000 description 23
- 238000002360 preparation method Methods 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- 244000061520 Angelica archangelica Species 0.000 description 20
- 201000010099 disease Diseases 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 19
- 239000000243 solution Substances 0.000 description 13
- 206010008479 Chest Pain Diseases 0.000 description 11
- 239000002671 adjuvant Substances 0.000 description 11
- 230000001717 pathogenic effect Effects 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 10
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 9
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 210000000038 chest Anatomy 0.000 description 9
- 229940010454 licorice Drugs 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- 238000002791 soaking Methods 0.000 description 7
- 206010007247 Carbuncle Diseases 0.000 description 6
- 206010010774 Constipation Diseases 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 230000002861 ventricular Effects 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- 208000029078 coronary artery disease Diseases 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 201000000736 Amenorrhea Diseases 0.000 description 4
- 206010001928 Amenorrhoea Diseases 0.000 description 4
- 235000017443 Hedysarum boreale Nutrition 0.000 description 4
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 4
- 208000006083 Hypokinesia Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 231100000540 amenorrhea Toxicity 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 4
- 230000004217 heart function Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000012827 research and development Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 3
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 206010040007 Sense of oppression Diseases 0.000 description 3
- 208000007814 Unstable Angina Diseases 0.000 description 3
- 229960005370 atorvastatin Drugs 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 201000009240 nasopharyngitis Diseases 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 206010013954 Dysphoria Diseases 0.000 description 2
- 201000000297 Erysipelas Diseases 0.000 description 2
- 208000015220 Febrile disease Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000405414 Rehmannia Species 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 240000007164 Salvia officinalis Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000010968 computed tomography angiography Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000024121 nodulation Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 208000000575 Arteriosclerosis Obliterans Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 241000723347 Cinnamomum Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000000770 Non-ST Elevated Myocardial Infarction Diseases 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 208000018997 giddiness Diseases 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 229940049103 isoproterenol injection Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 238000000874 microwave-assisted extraction Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 206010047470 viral myocarditis Diseases 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000011706 wistar kyoto rat Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/808—Scrophularia (figwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention aims to provide a traditional Chinese medicine composition for treating heat accumulation and blood vessels, which comprises the following raw material medicines: honeysuckle, figwort root, chinese angelica, liquorice, forsythia, cassia twig, giant knotweed and salvia miltiorrhiza.
Description
Technical Field
The application relates to a traditional Chinese medicine composition, in particular to a traditional Chinese medicine composition for treating heat accumulation and blood vessels, and belongs to the field of traditional Chinese medicines.
Background
The syndrome differentiation and treatment is a major characteristic of the clinical theory system of traditional Chinese medicine which is different from other medical systems. The research and development of new Chinese medicines are closely related to the syndrome theory of traditional Chinese medicine. At present, the clinical research of Chinese patent medicines mostly adopts a mode of combining diseases and symptoms, namely, the clinical research mode of chemical medicines is used for reference, and the mode has certain limitations by combining the functions and indications of new medicines and selecting the adaptation syndromes on the premise of definite disease diagnosis. The TCM treatment emphasizes the treatment based on syndrome differentiation, and the prescriptions are given according to the syndromes. Taking the pill of six ingredients with rehmannia as an example, if the pill of six ingredients with rehmannia is studied by simply applying the mode of disease and syndrome combination, the main treatment scope is confined to the kidney yin deficiency syndrome of a certain specific disease, the extension of the main treatment scope cannot be expanded, the treatment scope is greatly reduced, the treatment scope and the treatment effect of the traditional Chinese medicine cannot be fully developed, and the syndrome differentiation concept and the characteristics of the traditional Chinese medicine cannot be fully embodied.
Based on the concept of 'syndrome type new traditional Chinese medicine' provided, the 'syndrome type traditional Chinese medicine' is a new traditional Chinese medicine mainly used for treating the syndrome of the traditional Chinese medicine, is different from the traditional Chinese medicine mainly used for treating a certain syndrome of a certain disease, and has the research significance of exploring a new traditional Chinese medicine research and development mode which takes the syndrome as the center, accords with the traditional Chinese medicine diagnosis and treatment mode and can embody the traditional Chinese medicine characteristics. The medicine is different from a Chinese medicinal compound preparation mainly combined with diseases and symptoms, breaks away the disease concept of modern medicine, and is necessarily beneficial to developing the traditional characteristics of Chinese medicaments. Syndrome type traditional Chinese medicine takes syndrome as an intervention object, and based on the theory of treatment based on syndrome differentiation, treats different diseases simultaneously, embodies the holistic concept of traditional Chinese medicine, and is beneficial to evaluating the advantages and characteristics of traditional Chinese medicine, so the traditional Chinese medicine is concerned by a plurality of experts at the beginning of research and development. The Chinese patent medicine 'Liuwei Dihuang Wan' is a typical representative of the medicines, the application range of the Chinese patent medicine gets rid of the restriction of modern diseases, and since the Chinese patent medicine is on the market, the Chinese patent medicine is popular with the masses due to the characteristics of simplicity, convenience, low cost and wide application range, and the health service capability of the Chinese medicine is greatly improved. Therefore, the research and development of the medicines will further promote the development of the traditional Chinese medicine industry.
Heat accumulation in the blood vessels means that the accumulation of heat and blood stasis in the blood vessels are difficult to resolve, and they are causticized and followed by the adverse circulation of heat accumulation, toxicity generation, mass accumulation and vessel damage. The main pathogenesis of the disease is that heat pathogen and tangible objects such as blood stasis, phlegm dampness and the like in blood vessels mutually beat and combine, and the disease is located in the blood vessels. First, it is a problem of "heat". Invisible heat has two main sources, one is the transformation of exogenous pathogenic factors into interior heat. For example, liu Wang element can resolve heat and generate fire. For different individuals, the pathways of pathogenic qi transforming into heat are different and closely related to the physical condition of the body and the nature of the pathogenic factors. The pathological products in the two blood vessels can be stagnated for a long time to transform into heat. For example, phlegm-dampness and blood stasis in blood vessels can all transform fire into heat. In addition, heat pathogen can be caused by preponderance of yin and yang and fire transformation from five emotions. Secondly, "knots" are the key pathogenesis. What are the cases of the pathogenic factors and the physical factors in the book Shang Han Lun examination syndrome? Also, water and blood are. The invisible pathogenic factors and the visible substances of the water-blood are mutually struggled to form the knot. Here, invisible pathogenic qi and visible substance, i.e., "water and blood", are both indispensable. Thirdly, the disease location is the "blood vessel". The blood vessels are extraordinary fu organs, have hollow shapes, are connected with heart and lung, are distributed on the whole body, are channels for circulating qi and blood, have the physiological characteristic of storing essence without discharging, and can keep the blood volume and quality relatively constant.
Disclosure of Invention
The application aims to provide a traditional Chinese medicine composition aiming at the traditional Chinese medicine syndrome of 'heat accumulation and blood vessels', and the traditional Chinese medicine composition provides a new treatment idea and means for clinical treatment of hypertension and coronary heart disease.
As one aspect of the present application, the present application provides a traditional Chinese medicine composition for treating heat accumulation and blood vessels, the traditional Chinese medicine composition comprises the following raw material medicines: honeysuckle, figwort root, chinese angelica, liquorice, forsythia, cassia twig, giant knotweed and salvia miltiorrhiza.
Preferably, the traditional Chinese medicine composition comprises the following raw material medicines: 5-30 parts of honeysuckle, 5-30 parts of figwort root, 3-18 parts of Chinese angelica, 3-18 parts of liquorice, 5-30 parts of weeping forsythia capsule, 5-30 parts of cassia twig, 3-18 parts of giant knotweed rhizome and 5-30 parts of salvia miltiorrhiza.
Further preferably, the traditional Chinese medicine composition comprises the following raw material medicines: 9-24 parts of honeysuckle, 9-24 parts of figwort, 5-15 parts of angelica, 5-15 parts of liquorice, 9-24 parts of fructus forsythiae, 9-24 parts of cassia twig, 5-15 parts of polygonum cuspidatum and 9-24 parts of salvia miltiorrhiza.
Further preferably, the traditional Chinese medicine composition comprises the following raw material medicines: 12-18 parts of honeysuckle, 12-18 parts of figwort, 7-12 parts of angelica, 7-12 parts of liquorice, 12-18 parts of fructus forsythiae, 12-18 parts of cassia twig, 7-12 parts of polygonum cuspidatum and 12-18 parts of salvia miltiorrhiza.
Most preferably, the traditional Chinese medicine composition comprises the following raw material medicines: 15 parts of honeysuckle, 15 parts of figwort root, 9 parts of Chinese angelica, 9 parts of liquorice, 15 parts of weeping forsythia, 15 parts of cassia twig, 9 parts of giant knotweed rhizome and 15 parts of salvia miltiorrhiza;
or 13 parts of honeysuckle, 17 parts of figwort, 8 parts of angelica, 11 parts of liquorice, 13 parts of forsythia, 17 parts of cassia twig, 8 parts of giant knotweed and 16 parts of salvia miltiorrhiza;
or 17 parts of honeysuckle, 13 parts of figwort, 11 parts of angelica, 8 parts of liquorice, 17 parts of forsythia, 13 parts of cassia twig, 11 parts of giant knotweed and 13 parts of salvia miltiorrhiza.
In the above technical scheme, the traditional Chinese medicine composition can be in any form composed of or prepared from the above raw materials, including: the raw materials are respectively crushed and then mixed to form the composition; or, the composition is obtained by mixing and crushing the raw material medicines; or mixing the above raw materials, extracting by conventional extraction method to obtain extract, refining and purifying to obtain effective components, and making into conventional oral dosage forms.
The conventional extraction method comprises soaking extraction, decocting extraction, reflux extraction, percolation extraction, ultrasonic extraction, microwave extraction, etc.; the extraction solvent comprises water or conventional organic solvent such as ethanol, methanol, ethyl acetate, petroleum ether, isopropanol, etc.; the refining and purifying process comprises extraction, column chromatography separation, high performance liquid chromatography separation and the like.
The conventional oral dosage forms include tablet, capsule, granule, pill, powder, and oral liquid. The preparation of the dosage form needs to be added with common pharmaceutically acceptable auxiliary materials, including: fillers, disintegrants, lubricants, suspending agents, binders, sweeteners, flavoring agents, preservatives, bases, and the like. The filler comprises: starch, pregelatinized starch, lactose, mannitol, chitin, microcrystalline cellulose, sucrose, etc.; the disintegrating agent comprises: starch, pregelatinized starch, microcrystalline cellulose, sodium carboxymethyl starch, crospolyvinylpyrrolidone, low-substituted hydroxypropylcellulose, croscarmellose sodium, etc.; the lubricant comprises: magnesium stearate, sodium lauryl sulfate, talc, silica, and the like; the suspending agent comprises: polyvinylpyrrolidone, microcrystalline cellulose, sucrose, agar, hydroxypropyl methylcellulose, and the like; the binder includes starch slurry, polyvinylpyrrolidone, hydroxypropyl methylcellulose, etc.
The traditional Chinese medicine composition can be fed in the form of an extract or prepared into particles besides being fed in the form of raw medicines. Therefore, as another aspect of the present application, the present application further provides a traditional Chinese medicine composition for treating heat-binding blood vessels, which comprises the following raw materials: honeysuckle extract, figwort extract, angelica extract, liquorice extract, forsythia extract, cassia twig extract, polygonum cuspidatum extract and salvia miltiorrhiza extract; wherein the extract is water extract or ethanol extract of each raw material medicine respectively, or is granule prepared from the extract according to the conventional process.
Preferably, the traditional Chinese medicine composition comprises the following raw materials: 5-30 parts of honeysuckle extract, 5-30 parts of figwort root extract, 3-18 parts of Chinese angelica extract, 3-18 parts of liquorice extract, 5-30 parts of forsythia extract, 5-30 parts of cassia twig extract, 3-18 parts of polygonum cuspidatum extract and 5-30 parts of salvia miltiorrhiza extract.
Further preferably, the traditional Chinese medicine composition comprises the following raw materials: 9-24 parts of honeysuckle extract, 9-24 parts of figwort root extract, 5-15 parts of Chinese angelica extract, 5-15 parts of liquorice extract, 9-24 parts of forsythia extract, 9-24 parts of cassia twig extract, 5-15 parts of giant knotweed extract and 9-24 parts of salvia miltiorrhiza extract.
Further preferably, the traditional Chinese medicine composition comprises the following raw materials: 12-18 parts of honeysuckle extract, 12-18 parts of figwort root extract, 7-12 parts of Chinese angelica extract, 7-12 parts of liquorice extract, 12-18 parts of forsythia extract, 12-18 parts of cassia twig extract, 7-12 parts of giant knotweed extract and 12-18 parts of salvia miltiorrhiza extract.
Most preferably, the traditional Chinese medicine composition comprises the following raw materials: 15 parts of honeysuckle extract, 15 parts of figwort extract, 9 parts of Chinese angelica extract, 9 parts of licorice extract, 15 parts of forsythia extract, 15 parts of cassia twig extract, 9 parts of giant knotweed extract and 15 parts of salvia extract.
The extracts are respectively water extracts or ethanol extracts of the raw material medicines.
In the formula of the invention, honeysuckle: sweet and cold; the functional indications are as follows: clear heat and remove toxicity, disperse wind-heat. Can be used for treating carbuncle, furuncle, sore throat, erysipelas, toxic heat, dysentery, wind-heat type common cold, epidemic febrile disease, and fever. Figwort root: sweet, bitter, salty and slightly cold; the functional indications are as follows: clearing heat and cooling blood; nourishing yin to reduce pathogenic fire; detoxify and dissipate nodulation. Can be used for treating heat entering nutrient-blood, macula due to warm toxin, yin impairment due to fever, crimson tongue with dipsosis, constipation due to body fluid consumption, bone-steaming cough, conjunctival congestion, pharyngalgia, diphtheria, scrofula, superficial infection, and skin ulcer. Chinese angelica: sweet, pungent and warm; the functional indications are as follows: tonify blood, activate blood, regulate menstruation, alleviate pain, moisten intestines to relieve constipation. Can be used for treating blood deficiency, sallow complexion, giddiness, palpitation, menoxenia, amenorrhea, dysmenorrhea, asthenia cold, abdominal pain, rheumatalgia, traumatic injury, superficial infection, pyocutaneous disease, intestinal dryness, and constipation. Licorice root: sweet and mild; the functional indications are as follows: tonify spleen and qi, clear heat and remove toxicity, dispel phlegm and stop cough, relieve spasm and pain, and harmonize the drugs. Can be used for treating weakness of spleen and stomach, asthenia, palpitation, short breath, cough, excessive phlegm, abdominal and limb spasm, pain, carbuncle, swelling, sore, and drug toxicity and strong nature. Fructus forsythiae: bitter and slightly cold; the functional indications are as follows: clear heat and remove toxicity, resolve swelling and dissipate nodulation, disperse wind-heat. Can be used for treating carbuncle, cellulitis, scrofula, acute mastitis, erysipelas, wind-heat type common cold, early stage of epidemic febrile disease, damp-heat invasion of nutrient, hyperpyrexia, polydipsia, coma, macula, and stranguria caused by heat. Cassia twig: pungent, sweet and warm; the functional indications are as follows: induce sweating and release muscles, warm and dredge meridians, strengthen yang and regulate qi, and smooth pulse and descend qi. Can be used for treating wind-cold type common cold, abdominal psychroalgia, blood cold amenorrhea, arthralgia, phlegm retention, edema, palpitation, and galloping. Giant knotweed rhizome: slightly bitter and cold; the functional indications are as follows: promoting diuresis, removing jaundice, clearing away heat and toxic materials, dispelling blood stasis, relieving pain, relieving cough, and eliminating phlegm. Can be used for treating jaundice due to damp-heat pathogen, stranguria with turbid urine, leukorrhagia, rheumatalgia, carbuncle, swelling, sore, scald due to hot water and fire, amenorrhea, abdominal mass, traumatic injury, and cough due to lung heat. Red sage root: bitter and slightly cold; the functional indications are as follows: promoting blood circulation, dispelling blood stasis, dredging meridians, relieving pain, clearing away heart-fire, relieving restlessness, cooling blood, and eliminating carbuncle. Can be used for treating thoracic obstruction, cardialgia, abdominal pain, hypochondriac pain, abdominal mass, pain due to heat-evil, vexation, insomnia, menoxenia, dysmenorrhea, amenorrhea, and pyocutaneous disease with swelling and pain.
The honeysuckle flower in the formula is a monarch drug, is sweet and cold in nature and enters the heart, and is good at clearing heat and removing toxicity; fructus forsythiae has the effects of clearing heat, detoxifying, dissipating stagnation and relieving swelling, angelica has the effects of activating blood and dissipating stasis, and radix scrophulariae has the effects of nourishing yin, reducing pathogenic fire, relieving swelling and detoxifying. Giant knotweed rhizome, rhizoma Polygoni Cuspidati has the effects of clearing heat, promoting blood circulation, and relieving constipation, and is used as adjuvant drug; licorice root, radix Glycyrrhizae is a guiding drug for clearing away heat and toxic materials, cinnamon twig, ramulus Cinnamomi, warming and activating meridians, activating yang, regulating qi, activating blood, removing blood stasis, clearing away the heart-fire, relieving restlessness, cooling blood and resolving carbuncles.
As another aspect of the invention, the invention provides application of the traditional Chinese medicine composition in preparing a medicine for treating diseases related to hot junction and blood vessels.
The diseases related to the hot junction blood vessels comprise but are not limited to coronary heart disease, hypertension, peripheral vasculitis, unstable angina, non-ST elevation myocardial infarction, lower limb arteriosclerosis obliterans and viral myocarditis.
The invention has the beneficial effects that: the Chinese medicinal composition is a prescription which is determined to be more effective and can be further developed and converted based on the Chinese medicinal clinical theory of syndrome differentiation and treatment, the characteristics of syndrome type new medicaments from clinic, the screening of a medicinal effect experiment and the evaluation requirement of the Chinese medicinal new medicaments. The composition can be used for treating heat accumulation and blood vessel syndrome, and has advantages of getting rid of modern diseases and enlarging application range. The research shows that the Chinese medicinal composition has good treatment effect on various diseases with heat accumulation and blood vessels as Chinese medicinal symptoms, such as coronary heart disease, hypertension and the like.
Detailed Description
The following examples are given for the detailed implementation and the specific operation procedures, but the scope of the present invention is not limited to the following examples.
Example 1
The formula is as follows: 15g of honeysuckle, 15g of figwort, 9g of angelica, 9g of raw liquorice, 15g of fructus forsythiae, 15g of cassia twig, 9g of giant knotweed and 15g of salvia miltiorrhiza;
the preparation method comprises the following steps: taking the raw materials according to a certain proportion, adding 10 times of water, soaking for 90 minutes, decocting and extracting for 30 minutes, and extracting for three times; mixing the extractive solutions, and concentrating to 2.242g crude drug/mL; adding adjuvants into the extract, and making into granule.
Example 2
13g of honeysuckle, 17g of figwort root, 8g of Chinese angelica, 11g of raw licorice, 13g of weeping forsythia, 17g of cassia twig, 8g of giant knotweed and 16g of salvia miltiorrhiza;
the preparation method comprises the following steps: taking the raw materials according to a proportion, adding 10 times of water, soaking for 90 minutes, decocting and extracting for 30 minutes, and extracting for three times; mixing the extractive solutions, and concentrating to 2.242g crude drug/mL; adding adjuvants into the extract, and making into capsule.
Example 3
17g of honeysuckle, 13g of figwort root, 11g of Chinese angelica, 8g of raw liquorice, 17g of weeping forsythia, 13g of cassia twig, 11g of giant knotweed and 13g of salvia miltiorrhiza.
The preparation method comprises the following steps: taking the raw materials according to a certain proportion, adding 10 times of water, soaking for 90 minutes, decocting and extracting for 30 minutes, and extracting for three times; mixing the extractive solutions, and concentrating to 2.242g crude drug/mL; adding adjuvants into the extract, and making into tablet.
Example 4
14g of honeysuckle, 16g of figwort root, 7g of Chinese angelica, 10g of raw licorice, 14g of weeping forsythia, 16g of cassia twig, 7g of giant knotweed and 17g of salvia miltiorrhiza;
the preparation method comprises the following steps: taking the raw materials according to a certain proportion, adding 75% ethanol, and performing reflux extraction twice; mixing extractive solutions, volatilizing ethanol, adding adjuvant, and making into granule.
Example 5
16g of honeysuckle, 14g of figwort root, 10g of Chinese angelica, 7g of raw liquorice, 16g of weeping forsythia, 14g of cassia twig, 10g of giant knotweed and 14g of salvia miltiorrhiza.
The preparation method comprises the following steps: taking the raw materials according to a certain proportion, adding 75% ethanol, and performing reflux extraction twice; mixing the extractive solutions, evaporating ethanol, adding adjuvants, and making into capsule.
Example 6
10g of honeysuckle, 22g of figwort root, 5g of Chinese angelica, 14g of raw liquorice, 10g of weeping forsythia, 22g of cassia twig, 5g of giant knotweed and 22g of salvia miltiorrhiza;
the preparation method comprises the following steps: taking the raw materials according to a certain proportion, adding 75% ethanol, and performing reflux extraction twice; mixing extractive solutions, volatilizing ethanol, adding adjuvant, and making into tablet.
Example 7
22g of honeysuckle, 10g of figwort root, 14g of angelica, 5g of raw liquorice, 22g of fructus forsythiae, 5g of cassia twig, 14g of giant knotweed rhizome and 10g of salvia miltiorrhiza.
The preparation method comprises the following steps: the raw material medicines are taken according to a certain proportion, and are crushed and added with auxiliary materials to prepare granules.
Example 8
11g of honeysuckle, 20g of figwort root, 6g of Chinese angelica, 13g of raw liquorice, 11g of weeping forsythia, 20g of cassia twig, 6g of giant knotweed and 20g of salvia miltiorrhiza;
the preparation method comprises the following steps: the raw material medicines are taken according to a certain proportion, and are crushed and added with auxiliary materials to prepare tablets.
Example 9
20g of honeysuckle, 11g of figwort root, 13g of Chinese angelica, 6g of raw licorice, 20g of weeping forsythia, 6g of cassia twig, 13g of giant knotweed rhizome and 11g of salvia miltiorrhiza.
The preparation method comprises the following steps: the raw material medicines are taken according to a certain proportion, and are crushed and added with auxiliary materials to prepare capsules.
Example 10
7g of honeysuckle, 28g of figwort root, 3g of Chinese angelica, 17g of raw licorice, 7g of weeping forsythia, 28g of cassia twig, 3g of giant knotweed and 28g of salvia miltiorrhiza;
the preparation method comprises the following steps: taking the raw materials according to a certain proportion, adding 50% ethanol, and performing reflux extraction twice; mixing extractive solutions, volatilizing ethanol, adding adjuvant, and making into tablet.
Example 11
28g of honeysuckle, 7g of figwort root, 17g of angelica, 3g of raw liquorice, 28g of fructus forsythiae, 7g of cassia twig, 17g of giant knotweed rhizome and 6g of salvia miltiorrhiza.
The preparation method comprises the following steps: taking the raw materials according to a certain proportion, adding 50% ethanol, and performing reflux extraction twice; mixing extractive solutions, evaporating ethanol, adding adjuvant, and making into granule.
Example 12
8g of honeysuckle, 25g of figwort, 4g of angelica, 16g of raw liquorice, 8g of fructus forsythiae, 25g of cassia twig, 4g of giant knotweed and 25g of salvia miltiorrhiza;
the preparation method comprises the following steps: taking the raw materials according to a certain proportion, adding 50% ethanol, and performing reflux extraction twice; mixing extractive solutions, volatilizing ethanol, adding adjuvant, and making into capsule.
Example 13
Honeysuckle flower 25g, figwort root 8g, chinese angelica root 16g, licorice root 4g, capsule of weeping forsythia 25g, cassia twig 8g, giant knotweed rhizome 16g and root of red rooted saliva 8g.
The preparation method comprises the following steps: taking the raw materials according to a certain proportion, adding 50% ethanol, and performing reflux extraction twice; mixing extractive solutions, volatilizing ethanol, adding adjuvant, and making into dripping pill.
Example 14
The formula is as follows: 15g of honeysuckle extract, 15g of figwort root extract, 9g of Chinese angelica extract, 9g of raw licorice extract, 15g of forsythia extract, 15g of cassia twig extract, 9g of giant knotweed extract and 15g of salvia miltiorrhiza extract;
the above extracts are water extracts obtained by extracting the raw materials with water.
Example 15
13g of honeysuckle extract, 17g of figwort extract, 8g of angelica extract, 11g of raw licorice extract, 13g of forsythia extract, 17g of cassia twig extract, 8g of polygonum cuspidatum extract and 16g of salvia miltiorrhiza extract;
the above extracts are water extracts obtained by extracting the raw materials with water.
Example 16
17g of honeysuckle extract, 13g of figwort extract, 11g of angelica extract, 8g of raw licorice extract, 17g of forsythia extract, 13g of cassia twig extract, 11g of polygonum cuspidatum extract and 13g of salvia miltiorrhiza extract.
The above extracts are water extracts obtained by extracting the raw material medicines with water respectively.
Example 17
14g of honeysuckle extract, 16g of figwort extract, 7g of angelica extract, 10g of raw licorice extract, 14g of forsythia extract, 16g of cassia twig extract, 7g of polygonum cuspidatum extract and 17g of salvia miltiorrhiza extract;
the above extracts are water extracts obtained by extracting the raw materials with water.
Example 18
16g of honeysuckle extract, 14g of figwort root extract, 10g of Chinese angelica extract, 7g of raw licorice extract, 16g of forsythia extract, 14g of cassia twig extract, 10g of giant knotweed extract and 14g of salvia extract.
The above extracts are respectively alcohol extracts obtained by extracting raw materials with 75% ethanol.
Example 19
10g of honeysuckle extract, 22g of figwort root extract, 5g of Chinese angelica extract, 14g of raw licorice extract, 10g of forsythia extract, 22g of cassia twig extract, 5g of giant knotweed extract and 22g of salvia miltiorrhiza extract;
the above extracts are respectively alcohol extracts obtained by extracting raw materials with 75% ethanol.
Example 20
22g of honeysuckle extract, 10g of figwort extract, 14g of angelica extract, 5g of raw licorice extract, 22g of forsythia extract, 5g of cassia twig extract, 14g of polygonum cuspidatum extract and 10g of salvia miltiorrhiza extract.
The above extracts are respectively alcohol extracts obtained by extracting raw materials with 75% ethanol.
Example 21
11g of honeysuckle extract, 20g of figwort extract, 6g of angelica extract, 13g of raw licorice extract, 11g of forsythia extract, 20g of cassia twig extract, 6g of polygonum cuspidatum extract and 20g of salvia miltiorrhiza extract;
the above extracts are respectively alcohol extracts obtained by extracting raw materials with 75% ethanol.
Example 22
20g of honeysuckle extract, 11g of figwort extract, 13g of angelica extract, 6g of raw licorice extract, 20g of forsythia extract, 6g of cassia twig extract, 13g of polygonum cuspidatum extract and 11g of salvia miltiorrhiza extract.
The above extracts are respectively alcohol extracts obtained by extracting raw materials with 50% ethanol.
Example 23
7g of honeysuckle extract, 28g of figwort extract, 3g of angelica extract, 17g of raw licorice extract, 7g of forsythia extract, 28g of cassia twig extract, 3g of polygonum cuspidatum extract and 28g of salvia miltiorrhiza extract;
the above extracts are respectively alcohol extracts obtained by extracting raw materials with 50% ethanol.
Example 24
28g of honeysuckle granules, 7g of figwort granules, 17g of angelica granules, 3g of raw licorice granules, 28g of forsythia granules, 7g of cassia twig granules, 17g of polygonum cuspidatum granules and 6g of salvia miltiorrhiza granules.
The granules are respectively granules obtained by concentrating, drying and granulating extracts obtained by extracting raw material medicines with water.
Example 25
8g of honeysuckle granules, 25g of figwort granules, 4g of angelica granules, 16g of raw liquorice granules, 8g of forsythia granules, 25g of cassia twig granules, 4g of polygonum cuspidatum granules and 25g of salvia miltiorrhiza granules;
the granules are respectively granules obtained by concentrating, drying and granulating extracts obtained by extracting raw material medicines with water.
Example 26
Honeysuckle granules 25g, figwort granules 8g, angelica granules 16g, raw licorice granules 4g, forsythia granules 25g, cassia twig granules 8g, giant knotweed granules 16g and salvia granules 8g.
The granules are respectively granules obtained by concentrating, drying and granulating extracts obtained by extracting raw material medicines with water.
Effect test
1 blood pressure reduction effect experiment of the traditional Chinese medicine composition on SHR hypertensive rats
1.1 prescription and preparation method of medicine
Prescription: 15g of honeysuckle, 15g of figwort root, 9g of Chinese angelica, 9g of raw licorice, 15g of weeping forsythia, 15g of cassia twig, 9g of giant knotweed and 15g of salvia miltiorrhiza. Adding 10 times of water, soaking for 90 minutes, decocting and extracting for 30 minutes, and extracting for three times. Mixing extractive solutions, and concentrating to 2.242g crude drug/mL.
Four seconds Yongan' an decoction: honeysuckle flower 15g, scrophularia root 15g, chinese angelica root 9g and licorice root 9g. Adding 10 times of water, soaking for 90 minutes, decocting and extracting for 30 minutes, and extracting for three times. Mixing extractive solutions, and concentrating to 2.242g crude drug/mL.
1.2 animal grouping and modeling
60 male SHR rats, 8 weeks old, 180-200g in weight, were purchased from Beijing Wintolidhua laboratory animal technology Co., ltd (certification number: SCXK (Jing) 2016-0006). Feeding 5 animals in 5 cages of institute of basic theory of traditional Chinese medicine of Chinese academy of sciences, and feeding with mixed formula feed (Aojieli feed Co., ltd., beijing Ke) while freely taking water.
After the animals are fed for 3 days adaptively, SHR rats are randomly divided into a high dose group, a medium dose group, a low dose group, a Simiaoyong decoction group, an avavastatin positive drug control group and a model group by adopting a random digital table method. An alternative 10 WKY rats were normal controls. The high, medium and low dose groups are administered in a dose of 10, 5, 2.5 times the daily dose for an adult of 70 kg body weight. The control group and the model group were given the same volume of distilled water. The gavage amount is 20mL/kg body weight. The tail vein of each group of animals was measured for blood pressure after 4 weeks.
The high dose group animals were dosed at 10-fold the clinically equivalent dose (2.242 g crude drug/mL, 0.2mL/10g body weight);
the animals in the medium dose group are administered with 5 times of clinically equivalent dose (1.121 g crude drug/mL, 0.2mL/10g body weight);
the animals in the low dose group were administered 2.5 times the clinically equivalent dose (0.560 g crude drug/mL, 0.2mL/10g body weight);
the animals of the positive drug group were gavaged with atorvastatin (135 mg dissolved in 50ml water).
1.3 results of the experiment
The results are shown in Table 1.
TABLE 1 blood pressure levels in various groups of animals: (
n＝10)
Note: "" indicates P < 0.05 in comparison to control; ". DELTA" indicates that P < 0.05 was compared between the administered group and the model group.
The results of the study suggest that atorvastatin and the low dose group can effectively reduce the blood pressure of SHR hypertensive rats.
2 the influence of the traditional Chinese medicine composition on the animal model of chronic myocardial ischemia
2.1 prescription and preparation method of medicine
Prescription: 15g of honeysuckle, 15g of radix scrophulariae, 9g of angelica sinensis, 9g of raw liquorice, 15g of fructus forsythiae, 15g of cassia twig, 9g of polygonum cuspidatum and 15g of salvia miltiorrhiza. Adding 10 times of water, soaking for 90 min, decocting for 30 min, and extracting for three times. Mixing extractive solutions, and concentrating to 2.242g crude drug/mL.
2.2 animal grouping and modeling
Experimental animals were purchased from laboratory animals, vantonlifua, beijing. Clean grade, body mass (20 + -2) g,8 week C57BL/6J and ApoE-/-mice were selected. 10C 57BL/6J mice were used as normal control group and fed with normal diet for 6 weeks. 50 ApoE-/-mice were divided into a model group, a high dose group, a medium dose group, a low dose group and a positive drug group, 10 animals per group were fed with a high fat diet for 6 weeks, and isoproterenol (10 mg/kg) was subcutaneously injected in an amount of 0.02mL/g daily for 7d before the mice died, and an equal amount of physiological saline was administered to the blank group. Animal body weights were recorded weekly. 6 hours after the last isoproterenol injection, the animals were tested for cardiac function using a small animal ultrasound imager.
The high dose group animals were dosed at 10-fold the clinically equivalent dose (2.242 g crude drug/mL, 0.2mL/10g body weight);
the animals in the medium dose group are administered in 5-fold clinical equivalent dose (1.121 g crude drug/mL, 0.2mL/10g body weight)
The low dose animals were dosed at 2.5 times the clinically equivalent dose (0.560 g crude drug/mL, 0.2mL/10g body weight)
The positive drug group animal was gavaged with atorvastatin (135 mg dissolved in 50ml water).
2.3 results of the experiment
The results are shown in tables 2 and 3.
TABLE 2 detection results of cardiac function index of each group of animals
Note: "+" indicates P < 0.05 in the model group compared to the control group;
IVSd (end diastolic chamber interval thickness), IVSs (end systolic chamber interval thickness), LVPWd (end diastolic wall thickness), LVPWs (end systolic wall thickness), EF (ejection fraction), HR (heart rate).
TABLE 3 detection results of cardiac function index of each group of animals
Note: "+" indicates P < 0.05 in the model group compared to the control group;
LVIDd (end-diastolic left ventricular diameter), LVIDs (end-systolic left ventricular diameter), LVVold (end-diastolic left ventricular volume), LVVols (end-systolic left ventricular volume), FS% (minor axis shortening rate), LVm (ventricular Mass), LV Mass Corrected (left ventricular Mass index after correction).
Research results show that the traditional Chinese medicine composition can obviously improve the cardiac function of the chronic myocardial ischemia mouse.
3 clinical medical record
A certain woman in the age of 56 mainly complains about acupuncture pain in the chest and oppression in the chest, aggravates 1 week, and has a doctor before 3, 15 days in 2020: patients complain about chest oppression unsmooth before and after the spring festival in this year, heart rate is fast, chest stabbing pain is caused in nearly 3 days, chest oppression in chest is difficult to endure, whole body weakness is caused, constipation is caused, and coronary artery CT angiography (CTA) in a certain hospital is used for diagnosing coronary heart disease. The traditional Chinese medicine diagnoses obstruction of qi in the chest and heartache, dark red tongue, yellow and greasy tongue coating and smooth and rapid pulse, and accords with the diagnosis standard of the syndrome of heat accumulation and blood vessels of coronary heart disease. Prescription: 15g of honeysuckle, 15g of figwort root, 9g of Chinese angelica, 9g of raw licorice, 15g of weeping forsythia, 15g of cassia twig, 9g of giant knotweed and 15g of salvia miltiorrhiza. 14 the preparation is decocted in water for oral administration. And the 18-day consultation is carried out in 4 months in 2020: the self-describing chest pain and chest distress are relieved, the chest distress and hypodynamia, night sweat and soft stool exist at night, one line is daily, and the mouth is bitter. Dark tongue with white and greasy coating and a slippery and rapid pulse. Prescription: 15g of honeysuckle, 15g of radix scrophulariae, 9g of angelica sinensis, 9g of raw liquorice, 15g of fructus forsythiae, 15g of cassia twig, 9g of polygonum cuspidatum and 15g of salvia miltiorrhiza. 14 the preparation is decocted in water for oral administration. Three diagnoses in 5-month and 21-day 2020: the paroxysm of the heart beat is increased rapidly (110 to 120 times/min) in nearly 1 week, the chest is often stuffy at night, dizziness and hypodynamia are caused, the stool is thin after the medicine is taken, one line is taken every day, no mouth is dry, the mouth is bitter, and the chest pain disappears. Dark tongue with yellow, greasy and dry coating and deep, slippery and rapid pulse. Prescription: 15g of honeysuckle, 15g of radix scrophulariae, 9g of angelica sinensis, 9g of raw liquorice, 15g of fructus forsythiae, 15g of cassia twig, 9g of polygonum cuspidatum and 15g of salvia miltiorrhiza. 14 the preparation is decocted in water for oral administration. The disease condition is stable in half a year after follow-up visit, and no recurrence occurs.
Li a certain age, male, 60 years old, the patient complains of chest pain, occasionally attacks during sleep, frequently starting before 1 week and visiting 20 months before 2020: the patient mainly complains about chest distress and dysphoria before and after one month, chest pain occurs after slight exercise, and the patient is accompanied with whole body hypodynamia, short breath and constipation, and is diagnosed with unstable angina pectoris in electrocardiographic examination in a certain hospital. The traditional Chinese medicine diagnoses obstruction of qi in the chest and heartache, dry and bitter mouth, red tongue, yellow and greasy coating and smooth and rapid pulse, and accords with the diagnosis standard of unstable angina pectoris hot-junction blood vessel syndrome. Prescription: 15g of honeysuckle, 15g of radix scrophulariae, 9g of angelica sinensis, 9g of raw liquorice, 15g of fructus forsythiae, 15g of cassia twig, 9g of polygonum cuspidatum and 15g of salvia miltiorrhiza. 14 dosage is decocted in water for oral administration. The follow-up diagnosis is carried out in 2020, 8, 15 days: spontaneous chest pain and chest distress are relieved, spontaneous perspiration are accompanied, stool is soft, one row is taken every day, and the mouth is bitter. Dark tongue with white and greasy coating and a slippery and rapid pulse. Prescription: 15g of honeysuckle, 15g of radix scrophulariae, 9g of angelica sinensis, 9g of raw liquorice, 15g of fructus forsythiae, 15g of cassia twig, 9g of polygonum cuspidatum and 15g of salvia miltiorrhiza. 14 the preparation is decocted in water for oral administration. Three diagnoses in 9 and 20 days in 2020: after the self-telling excrement is taken, the excrement is thin, one line is taken every day, qi deficiency and hypodynamia are caused, no mouth is dry, the mouth is bitter, slight chest distress and dysphoria are caused, and chest pain disappears. A tongue with ecchymosis and petechia, a yellow and greasy coating and a slippery pulse. Prescription: 15g of honeysuckle, 15g of figwort root, 9g of Chinese angelica, 9g of raw licorice, 15g of weeping forsythia, 15g of cassia twig, 9g of giant knotweed and 15g of salvia miltiorrhiza. 14 the preparation is decocted in water for oral administration. The disease condition is stable in half a year after follow-up visit, and no recurrence occurs.
Claims (10)
1. A traditional Chinese medicine composition for treating heat accumulation and blood vessels is characterized by comprising the following raw material medicines: honeysuckle, figwort root, chinese angelica, liquorice, forsythia, cassia twig, giant knotweed and salvia miltiorrhiza.
2. The traditional Chinese medicine composition of claim 1, wherein the traditional Chinese medicine composition comprises the following raw material medicines: 5-30 parts of honeysuckle, 5-30 parts of figwort root, 3-18 parts of Chinese angelica, 3-18 parts of liquorice, 5-30 parts of weeping forsythia capsule, 5-30 parts of cassia twig, 3-18 parts of giant knotweed rhizome and 5-30 parts of salvia miltiorrhiza.
3. The traditional Chinese medicine composition of claim 2, wherein the traditional Chinese medicine composition comprises the following raw material medicines: 9-24 parts of honeysuckle, 9-24 parts of figwort root, 5-15 parts of Chinese angelica, 5-15 parts of liquorice, 9-24 parts of weeping forsythia capsule, 9-24 parts of cassia twig, 5-15 parts of giant knotweed rhizome and 9-24 parts of salvia miltiorrhiza.
4. The traditional Chinese medicine composition of claim 3, wherein the traditional Chinese medicine composition comprises the following raw material medicines: 12-18 parts of honeysuckle, 12-18 parts of figwort, 7-12 parts of angelica, 7-12 parts of liquorice, 12-18 parts of fructus forsythiae, 12-18 parts of cassia twig, 7-12 parts of polygonum cuspidatum and 12-18 parts of salvia miltiorrhiza.
5. The traditional Chinese medicine composition of claim 4, wherein the traditional Chinese medicine composition comprises the following raw material medicines: 15 parts of honeysuckle, 15 parts of figwort, 9 parts of angelica, 9 parts of liquorice, 15 parts of forsythia, 15 parts of cassia twig, 9 parts of giant knotweed and 15 parts of salvia miltiorrhiza;
or 13 parts of honeysuckle, 17 parts of figwort, 8 parts of angelica, 11 parts of liquorice, 13 parts of forsythia, 17 parts of cassia twig, 8 parts of giant knotweed and 16 parts of salvia miltiorrhiza;
or 17 parts of honeysuckle, 13 parts of figwort, 11 parts of angelica, 8 parts of liquorice, 17 parts of forsythia, 13 parts of cassia twig, 11 parts of giant knotweed and 13 parts of salvia miltiorrhiza.
6. The traditional Chinese medicine composition of any one of claims 1-5, wherein the traditional Chinese medicine composition is: the raw material medicines are respectively crushed and then mixed to form the composition; or the raw material medicines are mixed and then crushed to obtain the composition; or mixing the above raw materials, extracting by conventional extraction method to obtain extract, refining and purifying to obtain effective components, and making into conventional oral dosage form.
7. The traditional Chinese medicine composition of claim 6, wherein the conventional oral dosage form comprises tablets, capsules, granules, pills, powders, oral liquids.
8. A traditional Chinese medicine composition for treating heat accumulation and blood vessels is characterized by comprising the following raw materials: 5-30 parts of honeysuckle extract, 5-30 parts of figwort root extract, 3-18 parts of Chinese angelica extract, 3-18 parts of liquorice extract, 5-30 parts of forsythia extract, 5-30 parts of cassia twig extract, 3-18 parts of giant knotweed extract and 5-30 parts of salvia miltiorrhiza extract;
wherein the extracts are respectively water extracts or ethanol extracts of the raw material medicines.
9. The traditional Chinese medicine composition of claim 8, wherein the traditional Chinese medicine composition comprises the following raw materials: 9-24 parts of honeysuckle extract, 9-24 parts of figwort root extract, 5-15 parts of Chinese angelica extract, 5-15 parts of liquorice extract, 9-24 parts of forsythia extract, 9-24 parts of cassia twig extract, 5-15 parts of giant knotweed extract and 9-24 parts of salvia miltiorrhiza extract.
10. The traditional Chinese medicine composition of claim 9, wherein the traditional Chinese medicine composition comprises the following raw materials: 15 parts of honeysuckle extract, 15 parts of figwort extract, 9 parts of Chinese angelica extract, 9 parts of licorice extract, 15 parts of forsythia extract, 15 parts of cassia twig extract, 9 parts of giant knotweed extract and 15 parts of salvia extract.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021108964560 | 2021-08-05 | ||
| CN202110896456 | 2021-08-05 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115337348A true CN115337348A (en) | 2022-11-15 |
| CN115337348B CN115337348B (en) | 2023-10-24 |
Family
ID=83950780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210933899.7A Active CN115337348B (en) | 2021-08-05 | 2022-08-04 | Traditional Chinese medicine composition for treating heat-accumulation blood vessels |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115337348B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1824020A (en) * | 2005-12-14 | 2006-08-30 | 延边大学 | Medicine for treating coronary heart disease and its preparation method |
| CN101062183A (en) * | 2007-05-21 | 2007-10-31 | 王军 | Angelica sinensis granule for treating coronary heart disease |
| CN102210835A (en) * | 2011-06-10 | 2011-10-12 | 卢超忠 | Traditional Chinese medicine for treating coronary disease |
| CN106606592A (en) * | 2015-10-21 | 2017-05-03 | 肖忠剑 | Traditional Chinese medicine composition for treating coronary heart disease |
-
2022
- 2022-08-04 CN CN202210933899.7A patent/CN115337348B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1824020A (en) * | 2005-12-14 | 2006-08-30 | 延边大学 | Medicine for treating coronary heart disease and its preparation method |
| CN101062183A (en) * | 2007-05-21 | 2007-10-31 | 王军 | Angelica sinensis granule for treating coronary heart disease |
| CN102210835A (en) * | 2011-06-10 | 2011-10-12 | 卢超忠 | Traditional Chinese medicine for treating coronary disease |
| CN106606592A (en) * | 2015-10-21 | 2017-05-03 | 肖忠剑 | Traditional Chinese medicine composition for treating coronary heart disease |
Non-Patent Citations (4)
| Title |
|---|
| "全国名老中医治病经验谈系列——郑惠伯治冠心病——加味四妙勇安汤", 家庭医药, no. 06, pages 26 * |
| 林花;曲香芝;李嘉;陈正爱;: "金银花复方制剂对小鼠急性心肌缺血的保护作用", 延边大学医学学报, vol. 34, no. 02, pages 110 - 112 * |
| 胡镜清;: ""热结血脉"概论", 世界科学技术-中医药现代化, vol. 21, no. 10, pages 2005 - 2008 * |
| 谢连娣;陈立新;吴圣贤;聂波;: "四妙勇安汤治疗冠心病的临床和基础研究概述", 环球中医药, no. 08, pages 75 - 79 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115337348B (en) | 2023-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111388582B (en) | Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application of preparation thereof | |
| CN100431594C (en) | Compound preparation for treating summer wet type cold and its preparing method | |
| CN114224998B (en) | Traditional Chinese medicine composition, preparation and application for treating spleen-kidney yang deficiency type functional dyspepsia | |
| CN115227757B (en) | Application of traditional Chinese medicine composition in preparation of antihypertensive drugs | |
| CN115337347B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating coronary heart disease | |
| CN115337348B (en) | Traditional Chinese medicine composition for treating heat-accumulation blood vessels | |
| CN114712478B (en) | Traditional Chinese medicine composition for treating intestinal diseases, preparation and preparation method thereof | |
| CN101199806A (en) | Drug for treating laxness, preparing method and quality controlling method thereof | |
| CN103394002A (en) | Medicinal composition for treating cutaneous pruritus as well as preparation method and application thereof | |
| CN104800675A (en) | Medicament for treating active ulcerative colitis | |
| CN105833055A (en) | Traditional Chinese medicine composition for treating hypertension, hyperlipidemia and hyperglycemia and preparing method and application thereof | |
| CN101450117A (en) | Rheumatism treatment technique | |
| CN108143875B (en) | Traditional Chinese medicine composition for treating diabetic gastroparesis and preparation method thereof | |
| CN104337898B (en) | A kind of Chinese medicine composition of the treatment gout containing Semen Pruni | |
| CN116726083B (en) | Traditional Chinese medicine composition for treating chronic prostatitis | |
| CN101385810B (en) | Traditional Chinese medicine composition containing chinemys reevesii for treating dermatomyositis and preparation thereof | |
| CN116211974B (en) | Traditional Chinese medicine composition for improving microcirculation of human body | |
| CN102772540B (en) | A kind of medicine for the treatment of metabolism syndrome | |
| CN101385836B (en) | Traditional Chinese medicine composition containing poria cocos for treating dermatomyositis and preparation thereof | |
| CN107213323B (en) | Chinese medicinal compound preparation for nourishing yin, eliminating phlegm, resolving masses and detoxifying and application thereof | |
| CN107233410B (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis | |
| CN106361984A (en) | Nine-raw-material blood stanching powder and preparing method and application thereof | |
| CN118576648A (en) | Traditional Chinese medicine composition for treating community-acquired pneumonia and application thereof | |
| CN105663434A (en) | Traditional Chinese medicine for treating allergic cutaneous vasculitis and preparation method | |
| CN104352974A (en) | Ciliatenerve knotweed root-containing traditional Chinese medicine composition for treating diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231120 Address after: 712000 No.1, hancang South Road, high tech Industrial Development Zone, Qindu District, Xianyang City, Shaanxi Province Patentee after: SHAANXI MOMENTUM QIXUEHE PHARMACEUTICAL CO.,LTD. Address before: Room 217, No. 55, Xingfu First Village, Chaoyang District, Beijing 100700 Patentee before: China Science and Technology Development Center of Traditional Chinese Medicine (Talent Exchange Center of the State Administration of Traditional Chinese Medicine) |